Abbott Laboratories in its $20 billion senior notes offering

On February 23, 2026, Abbott Laboratories priced a registered public offering of $20.0 billion of senior notes.  Abbott intends to use the net proceeds from the offering, together with cash on hand and/or additional borrowings, to fund the consideration for its pending acquisition of Exact Sciences Corporation, to repay certain indebtedness of Exact Sciences, to pay related fees and expenses, and for general corporate purposes.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Abbott.